Abstract
PurposeTo evaluate if High-volume Image-guided Injection (HVIGI)-treatment for chronic mid-portion Achilles tendinopathy (AT) improve function and reduce pain at 12-months follow-up.MethodsPatients with resistant mid-portion AT who failed to improve after a three-month eccentric loading program were included in the study. Maximal tendon thickness was assessed with ultrasound. All patients were injected with 10 mL of 0.5% Marcaine, 0.5 mL Triamcinolonacetonid (40 mg/mL) and 40 mL of 0.9% NaCl saline solution under real-time ultrasound-guidance and high pressure. All outcome measures were recorded at baseline and 12 months. A standardized eccentric rehabilitation protocol was prescribed after HVIGI-treatment. Clinical outcome was assessed with the Victorian Institute of Sports Assessment-Achilles tendon questionnaire (VISA-A) and statistically analyses were performed.ResultsThe study included 30 single treatment HVIGI procedures in AT in 28 patients (23 men, 5 women) with a mean age of 45.1 (range 16–63). The mean duration of symptoms before HVIGI was 37 months. The baseline VISA-A score of 50 ± 15 (range 14–74) improved to 61 ± 21 (range 31–94) after 1 year (p = 0.04). Of the 30 AT procedures 10 patients (11 AT) were not satisfied after the initial HVIGI procedure. Of these, 8 patients (9 AT) needed additional HVIGI and two patients needed surgery. Of the remaining 18 patients (19 AT), 10 patients had more than a 10-point improvement in the VISA-A score after 1 year.ConclusionsIn this retrospective case-study, only 10 patients (33%) did benefit of a single HVIGI treatment at 12-months and an 11-point significant improvement was seen at on the VISA-A score.
Highlights
Achilles tendinopathy (AT) is a common overuse injury among runners
Patients were included if they had a diagnosis of tendinopathy in the mid-portion of the Achilles tendon and had failed a three-month eccentric training program (ET) program
Forty-two single treatment High-volume Image-guided Injection (HVIGI) procedures were performed in the period 2013–2016
Summary
Achilles tendinopathy (AT) is a common overuse injury among runners. Elite long-distance runners have a 52% risk of developing AT in their life span [1]. The prevalence and incident rate in the general population is 5.2 and 1.7– 2.3 per 1000 registered patients respectively [2, 3]. AT is a degenerative condition and is characterized by a Various treatment strategies for AT exist in the literature. A meta-analysis from 2012 advocated for eccentric training [6]. Other treatment modalities including shock wave, dry needling, corticoid injection, load
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
